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that the FDA will evaluate PRO recall periods. This study reviews the literature around 
PRO recall periods in the light of the ﬁnal guidance and provides recommendations 
to sponsors wishing to obtain FDA label claims on the basis of PRO endpoints. 
METHODS: A literature review was conducted in Embase and Medline, with further 
searching in Google scholar. References from each of the relevant papers were hand 
searched. Forty four papers were reviewed with reference to section D3 of the FDA 
ﬁnal PRO guidance, the research was summarized and a set of recommendations were 
developed. RESULTS: Psychological literature identiﬁes that recall of complex infor-
mation is problematic e.g. limited and selective memory and systemic biases. The 
majority of empirical work with PROs focuses on the measurement of pain with some 
evidence from fatigue measurement. Whilst most studies focus on symptoms, others 
examine HRQL, adherence and treatment satisfaction. Empirical research suggests a 
lack of correlation between actual experienced symptoms and recalled symptoms, with 
variability in patient attention to the recall period instruction. Recall is signiﬁcantly 
inﬂuenced by the concept being measured and attributes of the patient at the time of 
assessment. The ﬁndings from the research are in line with the FDA concerns and their 
preference for shorter recall periods. CONCLUSIONS: The ﬁnal FDA PRO guidance 
takes a considered approach to PRO recall periods in light of available research. 
Recommendations are presented on how best to select and justify the most appropriate 
recall period for a PRO measure in order to support regulatory review of drug 
approval label claims.
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Missing outcomes data in clinical trials can be detrimental to identifying important 
treatment effects because power is reduced and uncertainty is increased. Although 
missingness at the scale level for patient-reported outcomes (PROs) (e.g., due to 
attrition) is a considerable challenge to measurement in longitudinal clinical trials, 
missingness at the item level for PROs (e.g., due to omission) can be more easily 
overcome and a reliable scale score calculated. The FDA PRO Guidance states that 
the maximum tolerable number of missing item-level responses should be determined 
during the instrument development process, but no particular method is advocated, 
and instrument developers often recommend arbitrary guidelines. Although a number 
of methods exist for examining the effect of missing data on scale precision, one 
simple approach is to calculate Cronbach’s coefﬁcient alpha sequentially as each 
item is deleted from the item set. The order in which items are removed from the 
item set is based on deleting the item with the largest contribution to alpha (i.e., 
alpha-if-item-deleted). When Cronbach’s alpha for the set of remaining items falls 
below an a priori identiﬁed threshold (e.g., 0.70), the number of items deleted from 
the scale minus one is the maximum number of responses that can be missing for 
a scale score to be reliably calculated for a subject. We explored this approach with 
several validated instruments and found that the developer’s guidelines are often 
stricter than the alpha-if-item-deleted method. Broader application of the Cronbach’s 
alpha approach would result in fewer missing PRO scale scores, increased statistical 
power, reduced uncertainty, and additional information with which to assess treat-
ment effects.
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OBJECTIVES: 1)Understand how to navigate the regulatory environment, manage 
patient safety proﬁles, and achieve optimal process effectiveness in designing a Direct 
to Patient study; 2)Gather information on leveraging integrated technologies to 
support these studies; and 3)Learn key challenges and solutions from early Direct 
to Patient study implementations METHODS: The presentation will outline how to 
best design Direct to Patient studies to collect the right patient outcome data that 
will drive the most useful analysis. The presentation will look at the use of patient 
reported data to drive enrollment at the IND stage. Various methods of collecting 
patient data directly will be reviewed. RESULTS: Many questions are arising as the 
industry embarks on Direct to Patient programs, including how to navigate the 
regulatory challenges and various controls and guidelines. Other issues include how 
to address the changing role of investigators in this study model.Optimal roadmaps 
for designing Direct to Patient studies will be discussed, including the implementation 
of a ﬂexible clinical and medical infrastructure to monitor patient participation. 
Issues such as the shift from site management to patient management, the process 
for management from recruitment to retention, and the processes for adverse event 
follow-up will be discussed. The optimal use of technology, such as portals, Ran-
domization and Trial Supply Management technologies and ePRO data collection 
tools as well as the use of EDC in Direct to Patient programs will be discussed 
along with the right application of web-based and new social media tools. CON-
CLUSIONS: The increased need to have more outcomes and effectiveness data along 
with mounting pressure on the biopharmaceutical industry to contain costs have 
forced companies to look at new ways to manage studies more effectively and 
efﬁciently. There is a trend toward designing studies that reach out to patients 
directly in new ways, while at the same time eliminating costs and intermediaries 
associated with traditional studies.
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OBJECTIVES: The purpose of this conceptual work is to propose a transtheoretical 
framework for the development, selection, and evaluation of consumer technologies 
that promote individual health behaviors. To the best of our knowledge, this work is 
the ﬁrst of its kind to transcend the traditional “informatics/organizational interven-
tions” dyad to suggest, instead, an alternative conceptualization of technology rooted 
in theories of individual health behaviors, and one that acknowledges personal agency 
as a key factor vis a vis consumer technology decisions within the health context. 
CHALLENGE: Consumer technologies represent a hitherto untapped opportunity for 
encouraging afﬁrmative and beneﬁcial health behaviors on the individual level. 
Advances in information technologies including ubiquitous computing, social net-
working, and broadband Internet access have increased the scope and availability of 
health-related information. However, empirical evidence implicates the abundance of 
information sources as culprits in the widening knowledge gap among subpopulations 
of consumers. The relegation of technology to the realm of information-only is equally 
problematic for its presumed bias against uses of technology in “non-informatics” 
contexts, and for its apparent ignorance of the role of consumers as agents of their 
own health behaviors. RECOMMENDATION: We propose the novel application of 
The Transtheoretical Model (TTM) of Behavior Change at the critical intersection of 
consumer technologies and individual health behaviors. As we discuss in our work, 
TTM accommodates a consumer-focused vision of technology that is cognizant of the 
multi-stage, multi-process, and non-linear nature of human action in the context of 
adopting and maintaining health behaviors. We conclude our work with a list of 
principles informed by TTM to guide the development, selection, and evaluation 
of new and innovative technologies that encourage the adoption and maintenance of 
health behaviors by individual consumers.
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A combination of factors have contributed to an increased interest in patient-reported 
outcome (PRO) data. Increased chronic diseases and aging population, empowered 
patient group, a shift of treatment focus from curing diseases to ameliorating symp-
toms, as well as increasing budget constraint and competition among drugs developers 
are among the factors driving an increasing interest in assessing PROs. As the number 
and quantity of PROs increase, quality and criteria to assess these measures as well 
as sources of error and bias are increasingly being emphasized. A series of efforts were 
made in EU and the US to propose criteria for evaluating the scientiﬁc quality of PRO 
data in clinical practice. At the same time, major organizations sought to rationalize 
the ﬁeld and improve the standing of PRO assessments through open communications 
with key regulatory agencies including the FDA and the EMEA. Accordingly, issues 
related to methodological standards for measuring and interpreting PROs in the drug 
evaluation process were debated and the research agenda on PROs were expedited. 
Current major trends in PRO research include computerized adaptive testing (CAT), 
ePROs, and an integrated data collection. The adoption of CAT supported by modern 
psychometrics such as Item Response Theory (IRT) have the potential to achieve far 
greater precision in measuring health outcomes without increasing the response 
burden. However, crucial theoretical and methodological concerns need to be 
addressed before widely applying this approach in patient outcome research. ePROs 
have prevailed in clinical trials and shown high patient acceptance. The advantages 
of ePRO are evident. However, practical issues may be another hurdle before the 
practice is widely accepted in clinical research. Finally, as PRO data collection becomes 
more common in clinical trials, the coordination of integrated data collection may be 
of beneﬁt to all stakeholders.
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OBJECTIVES: Very few studies have attempted to document differences in patient 
satisfaction between ﬁrst and return visits. Therefore, we examined the differences in 
patient satisfaction with their primary care physician at ﬁrst visit compared to return 
visits. METHODS: We conducted a cross-sectional national web based survey study 
consisting of anonymous patients rating their physicians on the basis of treatment 
satisfaction received from their most recent outpatient visit. The user-friendly validated 
survey was designed to help patients identify their physicians as per specialties and 
rate them on a scale of 0 (“not at all satisﬁed”) to 10 (“extremely satisﬁed”). The 
association between satisfaction with primary care physician and patient ratings of 
total care between ﬁrst visit and return visits was accessed using robust regression 
analysis. RESULTS: A total of 9974 patients who rated physicians belonging to the 
categories of ﬁrst visit and return visits were included in this study. Other things being 
equal, return visits have a sizable effect on patient satisfaction. For unit change from 
ﬁrst to return visits the coefﬁcient of patient satisfaction for the return visits was 10.5 
